Genmab — December 2024
-
I know we don't have high royalty rates on Tec and Tal, but the development costs of those must be massive if you see all the data produced and trials run... no way Genmab would have been able to pull that off... will be a steady revenue stream for many years to come, at no cost or effort
-
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASH Annual Meeting 2024 -they mention 2 epco abstracts https://www.sitcancer.org/blogs/thomas-martin/2024/12/11/ash-annua
-
7/11 14:45 af Solsen
Epco looks like a blockbuster in 2026 at latest. And a multiblockbuster in years ahead. Hopefully a +$5bn. // 7/11 15:13
af E L
I think to get to $5bn we would need to also get CLL as indication? Jan spoke about an abstract at ASH i believe on CLL so hopefully that is a first step in deciding to pursue that area? -
Healthcare stocks fall as lawmakers push for bill to break up drug middlemen https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurer-stocks-fall-wsj-says-lawmakers-set-break-up-pharmacy-benefit-2024-12-11/ https://www.cnbc.com/2024/12/11/health-care-stocks-fall-after-warren-pbm-bill-brian-thompson-shooting.html
-
Nævnte de noget i går om, hvorfor beslutning om fremtiden for GEN1042 er blevet rykket til 2025?
-
i think that was already sort of clear from the Q3 call in Nov: JvdW: So for 1042, we are still collecting more data. And in the next months, we aim to take a decision on next steps. So we will be in the coming months, and we have collected all that data, different doses and dose frequency, we'll make a decision on next step for 1042 bispecific program.
-
Fra Nordea: “ Genmab (Hold) - Genmab var vært ved en R&D opdatering ifm. ASH konferencen. Ikke så meget nyt ift. data, men Genmab sagde, at de forventer at sende datatpakke til JNJ på Hexabody CD-38 inden årets udgang. Herefter starter uret og JNJ har 60 dage til at beslutte sig ift. udnyttelse af option. Vores bedste gæt er, at JnJ ikke udnytter optionen, da fremtidig fokus synes at være på bi-specifikke antistoffer og ikke mono-specifikke produkter som Hexabody CD-38.”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind